8-K: Recursion Reports Q2 2025 Results, Advances Pipeline

Recursion Pharmaceuticals reported increased revenue and significant net losses for Q2 2025, while advancing its clinical pipeline and securing a $7 million Sanofi milestone payment.

Summary

• Total revenue for Q2 2025 was $19.2 million, up from $14.4 million in Q2 2024.
• Net loss for Q2 2025 was $171.9 million, compared to $97.5 million in Q2 2024.
• Research and development expenses increased to $128.6 million in Q2 2025 from $73.9 million in Q2 2024, primarily due to the Tempus agreement and Exscientia business combination.
• General and administrative expenses rose to $46.7 million in Q2 2025 from $31.8 million in Q2 2024, mainly due to the Exscientia integration.
• Cash, cash equivalents, and restricted cash stood at $533.8 million as of June 30, 2025, down from $603.0 million at December 31, 2024.
• The company expects its cash runway to extend into the fourth quarter of 2027.
• A $7 million milestone payment was received from Sanofi for an immunology program, marking the fourth partnered program milestone in 18 months.
• Recursion acquired full rights to REC-102 (ENPP1 inhibitor) for hypophosphatasia (HPP) from its joint venture with Rallybio.
• The company expects to incur $9.3 million in restructuring costs in 2025, with $3.9 million already paid in Q2 2025.
• REC-1245 (RBM39 degrader) Phase 1/2 DAHLIA study is enrolling select tumor types, with early safety and PK data expected in 1H26.
• REC-617 (CDK7 inhibitor) combination dose escalation for platinum-resistant ovarian cancer initiated in 1H25, with additional monotherapy data expected in 2H25.
• REC-4539 (LSD1) for Small-Cell Lung Cancer is on strategic pause.

Sentiment

Score: 5

Explanation: The financial results show a significant increase in net loss and operating expenses, and a higher cash burn, which are negative. However, these are partially offset by strong progress in the clinical pipeline, achievement of a Sanofi milestone, a long cash runway into Q4 2027, and positive outlooks on future partnership milestones and operating expense reduction. The strategic pause on one program is a minor negative. Overall, a mixed bag with significant financial challenges but strong operational and strategic progress.

Positives

• Total revenue increased by 33.3% to $19.2 million in Q2 2025 from $14.4 million in Q2 2024.
• Achieved a $7 million milestone payment from Sanofi for an immunology program, the fourth partnered program milestone in 18 months.
• Acquired full rights to REC-102 (ENPP1 inhibitor) for hypophosphatasia (HPP), a potential first oral disease-modifying treatment.
• Expected cash runway extends into the fourth quarter of 2027.
• Anticipates over $100 million in partnership milestones by the end of 2026.
• Expected to reduce pro forma operating expenses by approximately 35% from 2024 to 2026 due to streamlining operations and infrastructure.
• Advanced multiple internal pipeline programs (REC-1245, REC-617, REC-7735, REC-4881, REC-3565) with upcoming data readouts and milestones.
• Boltz-2 open-source model for binding affinity prediction released, downloaded by over 40,000 unique users.
• ClinTech platform is expanding, integrating high-quality patient datasets to strengthen programs and optimize recruitment.

Negatives

• Net loss significantly increased to $171.9 million in Q2 2025 from $97.5 million in Q2 2024.
• Research and development expenses increased by 74% to $128.6 million in Q2 2025 from $73.9 million in Q2 2024.
• General and administrative expenses increased by 46.8% to $46.7 million in Q2 2025 from $31.8 million in Q2 2024.
• Net cash used in operating activities increased to $208.4 million for the six months ended June 30, 2025, from $184.5 million for the same period in 2024.
• Incurred $3.9 million in restructuring costs in Q2 2025, with total expected costs of $9.3 million in 2025.
• REC-4539 for Small-Cell Lung Cancer is on strategic pause to ensure a competitive Target Product Profile.

Risks

• Challenges inherent in pharmaceutical research and development, including high risk of failure at any stage prior to or after regulatory approval due to lack of sufficient efficacy, safety considerations, or other factors.
• Ability to leverage and enhance the drug discovery platform.
• Ability to obtain financing for development activities and other corporate purposes.
• Success of collaboration activities.
• Ability to obtain regulatory approval of, and ultimately commercialize, drug candidates.
• Ability to obtain, maintain, and enforce intellectual property protections.
• Cyberattacks or other disruptions to technology systems.
• Ability to attract, motivate, and retain key employees and manage growth.
• Inflation and other macroeconomic issues.

Future Outlook

The company expects its cash runway to extend into the fourth quarter of 2027, supported by anticipated partnership milestones exceeding $100 million by the end of 2026. Pro forma operating expenses are projected to decrease by approximately 35% from 2024 to 2026 due to operational streamlining. The internal pipeline is set to deliver key data readouts and development candidate nominations in 2H25 and 1H26, with Phase 1 initiations for REC-102 and REC-3565 expected in 2H26. Partnered discovery efforts with Sanofi, Roche/Genentech, Bayer, and Merck KGaA are advancing multiple programs towards development candidate designation over the next 12-15 months.

Management Comments

• "The power of our platform not only allows us to discover and develop potential new medicines, but also gives us insights on patient populations to target that would be challenging using traditional methods."
• "In discovery, we're deploying advanced models like Boltz-2 to rapidly design ligands for high-value targets. State of the art platform capabilities helped us drive our fourth partnered discovery milestone with Sanofi this quarter, reflecting tangible momentum across our joint pipeline."
• "We are leveraging these and other improvements to the Recursion OS to not only accelerate and improve our funnel of new programs, but also execution of later stage programs in our pipeline like RBM39 and CDK7."
• "For REC-617, our CDK7 inhibitor, we leveraged multi-omic and real world patient data and causal AI modeling to select platinum-resistant ovarian cancer as the first combination cohort."

Industry Context

This announcement highlights the growing trend of TechBio companies leveraging advanced AI, machine learning, and large-scale biological datasets to accelerate drug discovery and development. Recursion's focus on integrating wet-lab experiments with computational models, as exemplified by its Recursion OS 2.0 platform and partnerships with major pharmaceutical companies like Sanofi, Roche, Genentech, Bayer, and Merck KGaA, positions it at the forefront of this industry shift. The strategic pause on REC-4539 also reflects the industry's increasing emphasis on competitive target product profiles and data-driven decision-making in pipeline management.

Comparison to Industry Standards

• Time to candidate ID: Recursion averages significantly faster than the industry (e.g., 10-15 months vs. 40-50 months).
• Cost to IND: Recursion's cost to IND is significantly lower than industry averages (e.g., ~$10M vs. ~$25M).
• Highly productive compound design: Recursion synthesizes fewer compounds to candidate ID compared to industry (e.g., ~200-300 vs. ~1500-2000).
• Time to hit package: Recursion is significantly faster than industry (e.g., ~2-3 months vs. ~10-12 months).
• REC-4881 demonstrated significant reduction in polyp count in an APCmin/+ mouse model, outperforming celecoxib and decreasing both polyp number and pre-cancerous adenoma percentage.
• REC-7735 showed significant tumor regressions at low doses in preclinical models, outperforming clinically approved agents.

Stakeholder Impact

• Shareholders: Impacted by increased net losses and cash burn, but also by pipeline advancements, strategic partnerships, and a long cash runway, which could drive future value.
• Employees: Affected by the announced restructuring activities, which include associated costs.
• Patients: Potential for new, radically improved medicines through the advancement of multiple drug candidates in oncology and rare diseases.
• Partners (Sanofi, Roche/Genentech, Bayer, Merck KGaA): Benefit from continued collaboration progress and milestone achievements, leveraging Recursion's platform for drug discovery.
• Creditors: Financial health and cash runway are relevant for assessing creditworthiness.

Next Steps

• Additional data for REC-4881 (MEK1/2) in FAP from TUPELO expected in 2H25.
• Additional monotherapy data for REC-617 (CDK7) expected in 2H25.
• Development candidate nomination for REC-7735 (PI3K H1047R) expected in 2H25.
• Early Phase 1 safety and PK monotherapy data for REC-1245 (RBM39) expected in 1H26.
• Early Phase 1 safety and PK monotherapy data for REC-3565 (MALT1) expected in 2H26.
• Phase 1 initiation for REC-102 (ENPP1) expected in 2H26.
• Advancing several programs towards potential development candidate designation over the next 12-15 months.
• Building additional neuromaps, including multi-modal maps, with Roche and Genentech.
• Advancing multiple novel target and/or compound programs with Roche and Genentech.
• Work underway to advance multiple programs to lead series milestone decisions with Bayer.
• Continuing to expand the ClinTech platform, integrating high-quality, linked patient datasets.

Key Dates

Recommendation

While Recursion Pharmaceuticals reported a significant increase in net loss and operating expenses, leading to a higher cash burn in Q2 2025, the company maintains a strong cash position with an expected runway into Q4 2027. This provides ample time for pipeline progression. The achievement of a $7 million Sanofi milestone and the expectation of over $100 million in future partnership milestones underscore the value of its TechBio platform and collaborations. The strategic pause on REC-4539 is a minor setback, but the overall pipeline is advancing with multiple programs nearing key data readouts and development candidate nominations. The company's commitment to reducing operating expenses by 35% by 2026 is a positive sign for future financial efficiency. Given the high burn rate but also the significant long-term potential from its platform and pipeline, a 'hold' recommendation is appropriate, advising investors to monitor pipeline progress and financial efficiency closely.

Keywords

TechBio, drug discovery, AI, machine learning, oncology, rare disease, biotechnology, pharmaceuticals, clinical stage, SEC filing, RXRX, Recursion Pharmaceuticals, Sanofi, Roche, Genentech, Bayer, Merck KGaA, CDK7, RBM39, ENPP1, MEK1/2, PI3K H1047R, MALT1